JPMorgan analyst Tycho Peterson expects organic growth in the Life Science Tools & Diagnostics space to mirror 2019 against a "healthy backdrop" across biopharma and academic end markets. His top picks for 2020 are Danaher (DHR) and Thermo Fisher (TMO). The analyst also urges investors to take advantage of any downturn to add to "open-ended growth stories that trade at premium valuations," with Intuitive Surgical (ISRG) his top pick in this category. On the Smid-cap side, Peterson favors Guardant Health (GH), 10x Genomics (TXG) and NanoString (NSTG). For investors with a longer-term horizon, he recommend Adaptive Biotechnologies (ADPT). The analyst also continues to recommend Avantor (AVTR).

Barclays analyst Luke Sergott raised the firm's price target on Thermo Fisher to $615 from $590 and keeps an Equal Weight rating on the shares. The company reported a beat across the board, says the analyst, who sees the business stabilizing.

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here

Craig-Hallum assumed coverage of Guardant Health with a Buy rating with a price target of $28, down from $54. The firm remains bullish about the opportunities in therapy selection and are not all that concerned about emerging competition in liquid biopsy. Further, it is also bullish about the potential for Reveal, over time. Craig-Hallum thinks that there is a significant market for a tumor-naive MRD test. Tissue is simply not an option for all patients. Guardant appears to have the most viable test. Additionally, the firm believes the Shield colorectal screening test will be commercially viable, if FDA approved. The consensus view seems to be that there is no chance for this test to be included in the next USPSTF colon cancer screening recommendation. Craig-Hallum thinks that there is a reasonable likelihood that it will be included.

Baird raised the firm's price target on Danaher to $271 from $259 and keeps an Outperform rating on the shares. The firm said they reported 1Q results above expectations, helped by respiratory testing and bioprocessing upside. The company saw encouraging bioprocessing trends, with orders growing mid-single-digits, and noted normalization of large customer ordering patterns, with management expecting destocking to be largely complete by 2Q24-end.

Barclays raised the firm's price target on Danaher to $270 from $260 and keeps an Equal Weight rating on the shares post the Q1 report. The company's orders came in above expectations, the analyst tells investors in a research note. The firm says bioprocessing names continue to be favored by investors and that it does not see this changing in the near term.

Notable gainers among liquid option names this morning include Globe Life (GL) $71.33 +4.94, Super Micro (SMCI) $764.85 +47.83, Danaher (DHR) $250.88 +14.79, Kimberly Clark (KMB) $136.87 +7.94, and General Motors (GM) $45.38 +2.17.

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here